Dr. Archana S. Nagaraja

University of Texas MD Anderson Cancer Center, USA

Email: archin.sn@gmail.com

Qualifications

2017 Ph.D., The University of Texas Health Science Center, USA

2010 M.Sc., Drexel University, USA

Publications (Selected)

1. Nagaraja AS, Dood RL, Armaiz-Pena GN et al. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI-Insight, 2017; 2(16).
2. Nagaraja, A.S., Allen, J.A., Armaiz-Pena, G.N., Sadaoui, N.C., Dorniak, P.L., Herder D. M.et al. Sustained adrenergic signaling promotes intratumoral innerva4on through BDNF induc4on. (co first author). Cancer Research. 2017.
3. Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Nagaraja AS, et al. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metab. 2016; 24(5): 685-700.
4. Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, et al. Role of Increased nacetylaspartate Levels in Cancer. J Natl Cancer Inst. 2016; 108(6): djv426.
5. Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, et al. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene. 2016; 35(18): 2390-7.
6. Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Nagaraja AS, et al. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight. 2016; 1(17): e87754.
7. Nagaraja AS, Sadaoui NC, Dorniak PL, Lutgendorf SK, Sood AK. SnapShot: Stress and Disease. Cell Metab. 2016; 23(2): 388-e1.
8. Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Nagaraja AS, et al. Dll4 Inhibition plus Aflibercept markedly reduces ovarian tumor growth. Mol Cancer Ther. 2016; 15(6): 1344-52.
9. Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, et al. Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clin Cancer Res. 2016; 22(7): 1713-24.
10. Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, et al. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget. 2015; 6(6): 4266-73.
11. Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AK. Sympathetic nervous system regulation of the tumour microenvironment. Nat Rev Cancer. 2015; 15(9): 563-72.
12. Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, et al. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014; 5: 3459.
13. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Nagaraja AS, et al. Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013; 4: 1403.
14. Nagaraja AS, Sadaoui NC, Lutgendorf SK, Ramondema LM, Sood AK. beta-blockers: a new role in cancer chemotherapy? Expert Opin Investig Drugs. 2013; 22(11): 1359-63.
15. Nagaraja AS, Armaiz-Pena GN, Lutgendorf SK, Sood AK. Why stress is BAD for cancer patients. J Clin Invest. 2013; 123(2): 558-60